Related Experiment Video
Updated: Jun 7, 2025
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
4.3K
Nebivolol-Induced Hepatoxicity: A Case Report
Lynn Srour1, Majed Ali1, Karam Karam2
1Department of Internal Medicine, University of Balamand, Beirut, Lebanon.
European Journal of Case Reports in Internal Medicine
|November 11, 2024
Summary
Nebivolol, a selective beta-blocker, can cause liver injury. Monitoring liver function is crucial for patients taking nebivolol to detect and manage drug-induced hepatotoxicity early.
Area of Science:
- Cardiology
- Hepatology
- Pharmacology
Background:
- Nebivolol is a third-generation beta-blocker with high selectivity for beta-1 adrenergic receptors.
- It uniquely promotes vasodilation through nitric oxide (NO) release.
- Nebivolol generally has a favorable safety profile.
Purpose of the Study:
- To report a case of drug-induced liver injury associated with nebivolol.
- To highlight the importance of liver function monitoring in patients receiving nebivolol.
Main Methods:
- Case report of a 73-year-old hypertensive patient.
- Evaluation of liver enzyme elevations after nebivolol initiation.
- Exclusion of other potential causes of liver injury.
- Assessment of liver enzyme normalization after nebivolol discontinuation.
Main Results:
- The patient developed significant elevations in liver enzymes after starting nebivolol.
- Other causes of liver injury were ruled out through comprehensive workup.
- Discontinuation of nebivolol led to the normalization of liver enzymes.
Conclusions:
- Nebivolol can cause significant liver injury despite its favorable safety profile.
- Clinicians should monitor liver function routinely in patients prescribed nebivolol.
- Early detection and discontinuation of nebivolol are vital for managing drug-induced hepatotoxicity.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
319
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
319
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
407
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
407
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
707
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
707
01:26Heart Failure Drugs: Inotropic Agents
523
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
523
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
456
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
456